Targeting PD-1/PD-L1 in biliary tract cancer: role and available data

Reem D. Mahmood; Kathryn Graham; Jack Gleeson; Richard A. Hubner; Juan W. Valle; Mairéad G. Mcnamara

doi:10.2217/imt-2022-0190

Targeting PD-1/PD-L1 in biliary tract cancer: role and available data

Reem D. Mahmood
, Kathryn Graham
, Jack Gleeson
, Richard A. Hubner
, Juan W. Valle
, Mairéad G. Mcnamara

The Christie NHS Foundation Trust
University of Manchester

Research output: Contribution to journal › Review article › peer-review

Abstract

There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of patients with early-stage and advanced BTC. An Embase database search was conducted, identifying 15 eligible phase II/III clinical trials for review. Results from recent phase III trials show a statistically significant overall survival (OS) benefit from the addition of PD-1/PD-L1 inhibitors to chemotherapy in the first-line management of advanced BTC. Future research should concentrate on the discovery of biomarkers to identify patients who would benefit most from these therapies.

Original language	English
Pages (from-to)	517-530
Number of pages	14
Journal	Immunotherapy
Volume	15
Issue number	7
DOIs	https://doi.org/10.2217/imt-2022-0190
Publication status	Published - 1 May 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

biliary tract cancer
cholangiocarcinoma
immunotherapy
PD-1 inhibitor
PD-L1 inhibitor

Access to Document

10.2217/imt-2022-0190

Cite this

@article{7ba287c41d8d438fb9442e5e0ce3d850,

title = "Targeting PD-1/PD-L1 in biliary tract cancer: role and available data",

abstract = "There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of patients with early-stage and advanced BTC. An Embase database search was conducted, identifying 15 eligible phase II/III clinical trials for review. Results from recent phase III trials show a statistically significant overall survival (OS) benefit from the addition of PD-1/PD-L1 inhibitors to chemotherapy in the first-line management of advanced BTC. Future research should concentrate on the discovery of biomarkers to identify patients who would benefit most from these therapies.",

keywords = "biliary tract cancer, cholangiocarcinoma, immunotherapy, PD-1 inhibitor, PD-L1 inhibitor",

author = "Mahmood, \{Reem D.\} and Kathryn Graham and Jack Gleeson and Hubner, \{Richard A.\} and Valle, \{Juan W.\} and Mcnamara, \{Mair{\'e}ad G.\}",

note = "Publisher Copyright: {\textcopyright} 2023 Future Medicine Ltd.",

year = "2023",

month = may,

day = "1",

doi = "10.2217/imt-2022-0190",

language = "English",

volume = "15",

pages = "517--530",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - Targeting PD-1/PD-L1 in biliary tract cancer

T2 - role and available data

AU - Mahmood, Reem D.

AU - Graham, Kathryn

AU - Gleeson, Jack

AU - Hubner, Richard A.

AU - Valle, Juan W.

AU - Mcnamara, Mairéad G.

PY - 2023/5/1

Y1 - 2023/5/1

N2 - There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of patients with early-stage and advanced BTC. An Embase database search was conducted, identifying 15 eligible phase II/III clinical trials for review. Results from recent phase III trials show a statistically significant overall survival (OS) benefit from the addition of PD-1/PD-L1 inhibitors to chemotherapy in the first-line management of advanced BTC. Future research should concentrate on the discovery of biomarkers to identify patients who would benefit most from these therapies.

AB - There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of patients with early-stage and advanced BTC. An Embase database search was conducted, identifying 15 eligible phase II/III clinical trials for review. Results from recent phase III trials show a statistically significant overall survival (OS) benefit from the addition of PD-1/PD-L1 inhibitors to chemotherapy in the first-line management of advanced BTC. Future research should concentrate on the discovery of biomarkers to identify patients who would benefit most from these therapies.

KW - biliary tract cancer

KW - cholangiocarcinoma

KW - immunotherapy

KW - PD-1 inhibitor

KW - PD-L1 inhibitor

UR - https://www.scopus.com/pages/publications/85159235316

U2 - 10.2217/imt-2022-0190

DO - 10.2217/imt-2022-0190

M3 - Review article

C2 - 37009698

AN - SCOPUS:85159235316

SN - 1750-743X

VL - 15

SP - 517

EP - 530

JO - Immunotherapy

JF - Immunotherapy

IS - 7

ER -

Targeting PD-1/PD-L1 in biliary tract cancer: role and available data

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

New Cancer Study Findings Have Been Reported from The Christie NHS Foundation Trust (Targeting PD-1/PD-L1 in biliary tract cancer: role and available data)

Cite this

Targeting PD-1/PD-L1 in biliary tract cancer: role and available data

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Press/Media

New Cancer Study Findings Have Been Reported from The Christie NHS Foundation Trust (Targeting PD-1/PD-L1 in biliary tract cancer: role and available data)

Cite this